A Phase 2 Open-Label Study to Evaluate the Efficacy and Safety of Ustekinumab, a Human Monoclonal Anti-IL-12/IL-23 Antibody, in Patients With Behcet Disease

Trial Profile

A Phase 2 Open-Label Study to Evaluate the Efficacy and Safety of Ustekinumab, a Human Monoclonal Anti-IL-12/IL-23 Antibody, in Patients With Behcet Disease

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Mar 2017

At a glance

  • Drugs Ustekinumab (Primary)
  • Indications Behcet's syndrome
  • Focus Therapeutic Use
  • Acronyms STELABEC
  • Most Recent Events

    • 21 Mar 2017 Planned initiation date changed from 1 Oct 2016 to 1 Mar 2017.
    • 05 Jul 2016 Planned initiation date changed from 1 Feb 2016 to 1 Oct 2016.
    • 15 Feb 2016 Planned initiation date changed from 1 Jan 2016 to 1 Feb 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top